Share Price | Immuneering Corp. Stock Analysis & Recommendation

Q: Is Immuneering Corp. technically bullish or bearish?

As of 26 August 2025, the technical trend for Immuneering Corp. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish for both weekly and monthly periods. Daily moving averages indicate a bullish stance. The KST is bullish on both weekly and monthly time frames. However, the RSI shows a bearish signal for both weekly and monthly periods. Dow Theory indicates no trend on the weekly chart and a mildly bullish trend on the monthly chart. The OBV is also mildly bullish on a monthly basis.In terms of performance, Immuneering Corp. has significantly outperformed the S&P 500 over the past month with a return of 157.43% compared to the S&P 500's 2.33%, and year-to-date, it has returned 309.55% against the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the positive signals from moving averages and Bollinger Bands, despite the bearish RSI readings.

Q: Is Immuneering Corp. overvalued or undervalued?

As of 10 August 2022, the valuation grade for Immuneering Corp. moved from risky to does not qualify. The company is currently overvalued based on its financial metrics. Notable ratios include a Price to Book Value of 1.83, an EV to EBIT of -0.64, and an EV to EBITDA of -0.65, all indicating significant financial distress and loss-making status.In comparison with peers, Immuneering Corp. has a P/E ratio of -1.0602, while Ocular Therapeutix, Inc. has a P/E of -6.7319 and Akebia Therapeutics, Inc. has a P/E of -20.3063, highlighting that Immuneering is not the worst performer but still falls into a concerning category. The company's recent stock performance has outpaced the S&P 500, with a 1-year return of 70.63% compared to the index's 10.26%, yet this does not mitigate the overall valuation concerns.

Q: How big is Immuneering Corp.?

Market Cap: As of Jun 18, Immuneering Corp. has a market capitalization of 65.49 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Immuneering Corp. reported net sales of 0.00 million and a net profit of -61.78 million.Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 41.39 million, while total assets were reported at 52.71 million.

Q: What does Immuneering Corp. do?

Overview:Immuneering Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025)- Market cap: USD 65.49 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.85- Return on Equity: -147.64%- Price to Book: 1.57Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Results Declared: Immuneering Corp. has declared results on 05 Aug 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

174.69 k

Shareholding (Jun 2026)

FII

10.55%

Held by 42 FIIs

DII

84.23%

Held by 31 DIIs

Promoter

5.21%

Is Immuneering Corp. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Immuneering Corp. shows a bullish technical trend with strong moving averages and Bollinger Bands, despite bearish RSI signals, having outperformed the S&P 500 significantly over the past month and year-to-date.

View full answer

Is Immuneering Corp. overvalued or undervalued?

25-Jun-2025

As of August 10, 2022, Immuneering Corp. is considered overvalued with significant financial distress, reflected in its negative P/E ratio and other concerning metrics, despite a strong recent stock performance compared to the S&P 500.

View full answer

How big is Immuneering Corp.?

22-Jun-2025

As of Jun 18, Immuneering Corp. has a market capitalization of 65.49 million and reported net sales of 0.00 million with a net profit of -61.78 million over the latest four quarters. Shareholder's funds are 41.39 million, and total assets are 52.71 million.

View full answer

What does Immuneering Corp. do?

22-Jun-2025

Immuneering Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $15 million and a market cap of $65.49 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -147.64%.

View full answer

Compare Immuneering Corp. with Similar Stocks

Generation Bio Co.Sutro Biopharma, Inc.Praxis Precision Medicines, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 321 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.79

Return on Equity

-25.64%

Price to Book

1.47

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2026)

Net Profit:

-17 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.6%

6 Months

-8.52%

1 Year

28.49%

2 Years

295.61%

3 Years

-54.07%

4 Years

-29.53%

5 Years

-84.02%

Immuneering Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-208.11%

EBIT to Interest (avg)

-46.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.85

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

67.51%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.47

EV to EBIT

-2.50

EV to EBITDA

-2.52

EV to Capital Employed

3.22

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-128.94%

ROE (Latest)

-25.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 16 Schemes (27.24%)

Foreign Institutions

Held by 42 Foreign Institutions (10.55%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Mar 2026",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -28.15% vs -16.38% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.80",
          "val2": "-15.20",
          "chgp": "-23.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.30",
          "val2": "-13.50",
          "chgp": "-28.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.20% vs -14.02% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-58.70",
          "val2": "-63.40",
          "chgp": "7.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.00",
          "val2": "-61.00",
          "chgp": "8.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]